Abstract CT074: Pre-existing ESR1 mutations in early-stage primary breast cancer predict failure of endocrine therapy and poor survival
Malin Dahlgren(Lund University), Lao H. Saal(Domos (Norway)), Christer Larsson(Lund University), Åke Borg(Lund University), Johan Vallon‐Christersson(Lund University), Anna Ehinger(Lund University), Jari Häkkinen(Lund University), Christian Brueffer, Sergii Gladchuk(Lund University), Martin Malmberg(Skåne University Hospital), Sofia K. Gruvberger-Saal(Lund University), Yilun Chen(Lund University), Anthony M. George(Lund University), Cecilia Hegardt(Lund University), Niklas Loman(Lund University), Lisa Rydén(Lund University)
Cited by 1
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
|Nature Medicine|2001|2.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k